Skip to main content

Kymera Therapeutics, Inc.

corporate_fare Company Profile

Kymera Therapeutics, Inc.

KYMR·NASDAQ·Life Sciences·CIK 0001815442

We are a clinical-stage biopharmaceutical company focused on developing innovative oral medicines to treat human diseases. We aim to advance novel technologies to target disease-causing biology that has not been adequately addressed by existing treatments. Our approach is designed to discover and develop new medicines in a disease-agnostic manner. We are a leader in targeted protein degradation (TPD), a small molecule therapeutic method that uses the body's natural cellular recycling system to eliminate disease-causing proteins. Our goal is to develop potent and highly selective molecules to address diseases poorly served by current treatments. We have advanced multiple programs into clinical development and expect to advance at least one new molecular entity into clinical testing annually. We intend to become a fully integrated biopharmaceutical company with a pipeline of novel medicines. Our current discovery and development efforts primarily focus on high-value targets in immunology. We believe over 160 million patients in the United States, Europe, and Japan are diagnosed with prevalent immune-inflammatory diseases that our programs could address, with nearly half remaining untreated. Most treated patients receive therapies that address symptoms rather than underlying diseases. Approximately 3% of the diagnosed population with moderate to severe inflammatory diseases are currently treated with systemic advanced therapies, mostly injectable biologics. Biologics, while generally effective, are more expensive to manufacture, and patient access can be challenging due to prescription and reimbursement complexities compared to small molecule medicines.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for KYMR at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Kymera Therapeutics Q1 Revenue Jumps 55% to $34.4M, Advances Key Clinical Programs
  • Kymera Therapeutics Reports Q1 2026 Results, Secures $45M Gilead Milestone, and Gains Two Fast Track Designations
  • Kymera Therapeutics Reports Strong Q1 Revenue Growth, $45M Gilead Milestone, and Positive Pipeline Updates
  • FDA Grants Fast Track Designation to Kymera's First-in-Class Oral Asthma Drug KT-621
  • Kymera Therapeutics Establishes New $500M ATM Program and Registers Over 31M Shares for Resale by Key Investors

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$39.21M
Net Income
-$311.35M
Diluted EPS
-$3.69
Op. Cash Flow
-$232.89M
Free Cash Flow
-$234.34M
Gross Profit
$0
Operating Income
-$349.4M
Cash & Equivalents
$357.01M
Debt / Equity
0.00×
Net Margin
-7.94×
Shares Outstanding
81.32M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-073395
$124.06 +7.59% today
52-week range · as of 2026-10-29 $55.66 – $130.05
Market cap
$9.84B
Volume
1.3M (1.4× avg)
3-mo avg 931.1K
Live data · 2026-11-22 12:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed KYMR - Filings & News (Page 2)

KYMR
Apr 30, 2026, 7:21 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $83.97
Real-time Price: $124.06 info
Change: +$40.09 (+48%) info
Market Cap: $9.844B info
KYMR
Apr 30, 2026, 7:15 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $83.97
Real-time Price: $124.06 info
Change: +$40.09 (+48%) info
Market Cap: $9.844B info
KYMR
Apr 30, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $83.97
Real-time Price: $124.06 info
Change: +$40.09 (+48%) info
Market Cap: $9.844B info
KYMR
Apr 13, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $85.05
Real-time Price: $124.06 info
Change: +$39.01 (+46%) info
Market Cap: $9.844B info
KYMR
Feb 26, 2026, 8:22 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $83.50
Real-time Price: $124.06 info
Change: +$40.56 (+49%) info
Market Cap: $9.844B info
KYMR
Feb 26, 2026, 8:18 AM EST
Filing Type: 424B3
Importance Score:
9
Price at Filing: $83.50
Real-time Price: $124.06 info
Change: +$40.56 (+49%) info
Market Cap: $9.844B info
KYMR
Feb 26, 2026, 8:14 AM EST
Filing Type: 424B5
Importance Score:
7
Price at Filing: $83.50
Real-time Price: $124.06 info
Change: +$40.56 (+49%) info
Market Cap: $9.844B info
KYMR
Feb 26, 2026, 7:15 AM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $89.63
Real-time Price: $124.06 info
Change: +$34.43 (+38%) info
Market Cap: $9.844B info
KYMR
Feb 26, 2026, 7:10 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $89.63
Real-time Price: $124.06 info
Change: +$34.43 (+38%) info
Market Cap: $9.844B info
KYMR
Jan 13, 2026, 7:08 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $73.10
Real-time Price: $124.06 info
Change: +$50.96 (+70%) info
Market Cap: $9.844B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets